<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>To investigate the characteristic features of <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> in type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, Otsuka Long-Evans Tokushima fatty (OLETF) rats, an animal model of human type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo>, and non-diabetic Long-Evans Tokushima Otsuka (LETO) rats were fed with or without <z:chebi fb="27" ids="17992">sucrose</z:chebi> and/or an <z:chebi fb="0" ids="15693">aldose</z:chebi> reductase inhibitor, [5-(<z:chebi fb="0" ids="37992">3-thienyl</z:chebi>) tetrazol-1-yl] <z:chebi fb="22" ids="15366">acetic acid</z:chebi> (TAT), for 24 weeks, and physiological, biochemical and morphological assessments were performed </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="27" ids="17992">Sucrose</z:chebi> administration caused remarkable <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> in OLETF rats but not in LETO rats </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="27" ids="17992">Sucrose</z:chebi>-fed OLETF rats demonstrated <z:hpo ids='HP_0000762'>delayed nerve conduction velocity</z:hpo>, decreased coefficient of variation of R-R interval, reduced sciatic nerve blood flow, <z:mp ids='MP_0009586'>increased platelet aggregation</z:mp> activity, a lower concentration of erythrocyte <z:chebi fb="0" ids="19324">2,3-diphosphoglycerate</z:chebi>, and decreased <z:chebi fb="1" ids="29101">Na+</z:chebi>/K+-ATPase activity in sciatic nerves, compared with the non-<z:chebi fb="27" ids="17992">sucrose</z:chebi>-fed OLETF and LETO rats </plain></SENT>
<SENT sid="3" pm="."><plain>TAT prevented <z:hpo ids='HP_0000001'>all</z:hpo> these deficits except <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Sorbitol and <z:chebi fb="15" ids="28757">fructose</z:chebi> accumulation and <z:chebi fb="0" ids="17268">myo-inositol</z:chebi> <z:mpath ids='MPATH_63'>depletion</z:mpath> in tail nerves of <z:chebi fb="27" ids="17992">sucrose</z:chebi>-fed OLETF rats were ameliorated by TAT </plain></SENT>
<SENT sid="5" pm="."><plain>Myelinated fiber size and density in sural nerves of <z:chebi fb="27" ids="17992">sucrose</z:chebi>-fed OLETF rats were decreased and increased, respectively, compared with non-<z:chebi fb="27" ids="17992">sucrose</z:chebi>-fed OLETF and LETO rats </plain></SENT>
<SENT sid="6" pm="."><plain>These morphological abnormalities were normalized by TAT </plain></SENT>
<SENT sid="7" pm="."><plain>These observations suggest that the <z:chebi fb="27" ids="17992">sucrose</z:chebi>-fed OLETF rat developed <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> not only electrophysiologically but also histologically, and that an <z:chebi fb="0" ids="15693">aldose</z:chebi> reductase inhibitor, TAT, possesses therapeutic value for the treatment of <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e> </plain></SENT>
</text></document>